

## MEDICATION FOR OPIOID USE DISORDER TRAINING

1. 2019 NSDUH Detailed Tables. Samhsa.gov. Accessed June 11, 2021. <https://www.samhsa.gov/data/report/2019-nsduh-detailed-tables>
2. ASAM Definition of Addiction. Asam.org. Accessed June 11, 2021. <https://www.asam.org/Quality-Science/definition-of-addiction>
3. Asam.org. Accessed June 11, 2021. [https://www.asam.org/docs/default-source/advocacy/2021-medicare-pfs-final-rule-summary.pdf?Status=Temp&sfvrsn=126a59c2\\_2](https://www.asam.org/docs/default-source/advocacy/2021-medicare-pfs-final-rule-summary.pdf?Status=Temp&sfvrsn=126a59c2_2)
4. Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède, J.-P., & Tignol, J. (2004). French field experience with buprenorphine. *The American Journal on Addictions*, 13 Suppl 1(s1), S17-28.
5. Ball JC, Ross CA. *The Effectiveness of Methadone Maintenance Treatment* Springer-Verlag. Published online 1991.
6. Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies offered at residential addiction treatment programs in the United States. *JAMA*. 2020;324(8):804-806.
7. Buprenorphine FA. QUICK START GUIDE. Samhsa.gov. Accessed June 9, 2021. <https://www.samhsa.gov/sites/default/files/quick-start-guide.pdf>
8. Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. *bmj*. 2021;373.
9. CDC. (2019, February 11). Opioid overdoses treated in emergency departments. Retrieved June 14, 2021, from Cdc.gov website: <https://www.cdc.gov/vitalsigns/opioid-overdoses/index.html>
10. Childress AR, Mozley PD, McElgin W, Fitzgerald J, Reivich M, O'Brien CP. Limbic activation during cue-induced cocaine craving. *Am J Psychiatry*. 1999;156(1):11-18.
11. Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. *Drug Alcohol Depend*. 2018;193:117-123.
12. Daniulaityte R, Nahhas RW, Silverstein S, et al. Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis. *Drug Alcohol Depend*. 2019;204(107574):107574.
13. D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence: A randomized clinical trial. *JAMA*. 2015;313(16):1636.
14. Dora-Laskey, A., King, A., & Sadler, R. (2021). Identifying barriers to emergency department-initiated buprenorphine: A spatial analysis of treatment facility access in Michigan. *The American Journal of Emergency Medicine*, 51, 393–396. <https://doi.org/10.1016/j.ajem.2021.11.014>
15. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. *JAMA*. 1998;280(22):1936-1943.
16. Genberg, B. L., Gillespie, M., Schuster, C. R., Johanson, C.-E., Astemborski, J., Kirk, G. D., ... Mehta, S. H. (2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. *Addictive Behaviors*, 38(12), 2868–2873.
17. Greenwald MK. Effects of buprenorphine maintenance dose on  $\mu$ -opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. " *Neuropsychopharmacology*. 2003;28. 11:2000–2009.
18. Guo, C. Z., D'Onofrio, G., Fiellin, D. A., Edelman, E. J., Hawk, K., Herring, A., McCormack, R., Perrone, J., & Cowan, E. (2021). Emergency department-initiated buprenorphine protocols: A national evaluation. *Journal of the American College of Emergency Physicians Open*, 2(6), e12606. <https://doi.org/10.1002/emp2.12606>
19. Hawk, K., Hoppe, J., Ketcham, E., LaPietra, A., Moulin, A., Nelson, L., ... D'Onofrio, G. (2021). Consensus recommendations on the treatment of opioid use disorder in the emergency department. *Annals of Emergency Medicine*, 78(3), 434–442.

## Medication for Opioid Use Disorder Training (Continued)

21. Health and Human Services Department. Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Federal Register. 2021;86:22439-22440. <https://www.federalregister.gov/d/2021-08961>
22. Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. *Ann Emerg Med.* 2019;73(5):481-487.
23. Im, D. D., Chary, A., Condella, A. L., Vongsachang, H., Carlson, L. C., Vogel, L., ... & Samuels-Kalow, M. (2020). Emergency department clinicians' attitudes toward opioid use disorder and emergency department-initiated buprenorphine treatment: a mixed-methods study. *Western Journal of Emergency Medicine, 21(2)*, 261–271.
24. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. *N Engl J Med.* 2010;363(24):2320-2331.
25. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet.* 2003;361(9358):662-668.
26. Kazerouni, N. J., Irwin, A. N., Levander, X. A., Geddes, J., Johnston, K., Gostanian, C. J., ... Hartung, D. M. (2021). Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden. *Drug and Alcohol Dependence, 224*, 108729.
27. Kelly, J. C., Raghuraman, N., Stout, M. J., Russell, S., Perez, M., Nazeer, S., El Helou, N., Zhang, F., & Carter, E. (2021). Home induction of buprenorphine for treatment of opioid use disorder in pregnancy. *Obstetrics and Gynecology, 138(4)*, 655–659.
28. Kiang, M. V., Barnett, M. L., Wakeman, S. E., Humphreys, K., & Tsai, A. C. (2021). Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States. *Drug and Alcohol Dependence, 228(109081)*, 109081
29. Kohan, L., Potru, S., Barreveld, A. M., Sprintz, M., Lane, O., Aryal, A., Emerick, T., Dopp, A., Chhay, S., & Viscusi, E. (2021). Guidelines for the use of buprenorphine for opioid use disorder in the perioperative setting. *Regional Anesthesia and Pain Medicine, 46(10)*, 860–861. <https://doi.org/10.1136/rapm-2021-103092>
30. Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services: Opioid agonist treatment and overdose. *Addiction.* 2020;115(9):1683-1694.
31. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. *Lancet.* 2011;377(9776):1506-1513.
32. Lagisetty, P. A., Ross, R., Bohnert, A., Clay, M., & Maust, D. T. (2019). Buprenorphine treatment divide by race/ethnicity and payment. *JAMA Psychiatry (Chicago, Ill.)*, 76(9), 979–981.
33. LeSaint KT, Klapthor B, Wang RC, Geier C. Buprenorphine for opioid use disorder in the emergency department: A retrospective chart review. *West J Emerg Med.* 2020;21(5):1175-1181.
34. Link HM, Jones H, Miller L, Kaltenbach K, Seligman N. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. *Am J Obstet Gynecol MFM.* 2020;2(3):100179.
35. Ruddox V, Mathisen M, Otterstad JE. Prevalence and prognosis of non-specific chest pain among patients hospitalized for suspected acute coronary syndrome - a systematic literature search. *BMC Med.* 2012;10(1):58.
36. Samhsa.gov. Accessed June 11, 2021. <https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf>
37. Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. *J Subst Abuse Treat.* 2018;95:9-17.

## Medication for Opioid Use Disorder Training (Continued)

38. Schmidt A, Borgwardt S, Gerber H, et al. 2014. Acute effects of heroin on negative emotional processing: relation of amygdala activity and stress-related responses. *Biological Psychiatry* 76(4):289–296.
39. Schuler, M. S., Dick, A. W., & Stein, B. D. (2021c). Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017. *Drug and Alcohol Dependence*, 223(108710), 108710.
40. Schwartz RP, Gryczynski J, O’Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. *Am J Public Health*. 2013;103(5):917-922.
41. Sufrin, C., Sutherland, L., Beal, L., Terplan, M., Latkin, C., & Clarke, J. G. (2020). Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study. *Addiction (Abingdon, England)*, 115(11), 2057–2065.
42. Landis, R. K., Levin, J. S., Saloner, B., Gordon, A. J., Dick, A. W., Sherry, T. B., Leslie, D. L., Sorbero, M., & Stein, B. D. (2022). Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. *Substance Abuse: Official Publication of the Association for Medical Education and Research in Substance Abuse*, 43(1), 1057– 1071. <https://doi.org/10.1080/08897077.2022.2060424>
43. Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. *N Engl J Med*. 2016;374(4):363-371.
44. Wakeman SE, Larochele MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA Netw Open*. 2020;3(2):e1920622.
45. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. *Clin Pharmacol Ther*. 1994;55(5):569-580.
46. Webster LR, Hansen E, Cater J, Smith T. A phase I placebo-controlled trial comparing the effects of buprenorphine buccal film and oral oxycodone hydrochloride administration on respiratory drive. *Adv Ther*. 2020;37(11):4685-4696.
47. Weiner, S. G., Baker, O., Bernson, D., & Schuur, J. D. (2020). One-year mortality of patients after emergency department treatment for nonfatal opioid overdose. *Annals of Emergency Medicine*, 75(1), 13–17.
48. Wise RA, Koob GF. The development and maintenance of drug addiction. *Neuropsychopharmacology*. 2014;39(2):254-262.
49. Xu KY, Borodovsky JT, Presnall N, et al. Association between benzodiazepine or Z-drug prescriptions and drug-related poisonings among patients receiving buprenorphine maintenance: A case-crossover analysis. *Am J Psychiatry*. Published online 2021:appiajp202020081174.
50. Zweben JE, Sorensen JL, Shingle M, Blazes CK. Discontinuing methadone and buprenorphine: A review and clinical challenges. *J Addict Med*. 2020;Publish Ahead of Print. doi:10.1097/ADM.0000000000000789